Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
101
resultados
Última actualización
28/02/2026 [07:21:00]
Resumen de: US20260053741A1
The invention relates to a product for treating viral diseases, such as COVID-19, via the nasal route. The product comprises a hydrogel based on water, glycerol and a carbomer.
Resumen de: AU2024333842A1
The present invention relates to polypeptides, polynucleotides, compositions, microorganisms, vectors and vaccine compositions optimised for the treatment or prophylaxis of a disease or infection caused by Betacoronaviruses, including but not limited to: Embecovirus, Hibecovirus, Merbecovirus, Nobecovirus, Sarbecovirus, MERS-CoV, SARS-CoV-1 and SARS-CoV-2. In particular, the invention provides a vaccine composition comprising a polypeptide, wherein the polypeptide comprises one or more epitope sequences, wherein the one or more epitope sequences have the amino acid sequences of any one or more of the sequences of Table 1, or a variant thereof having at least 70% sequence identity thereto, and wherein the polypeptide sequence is no more than 1400 amino acids in length.
Resumen de: WO2026040166A1
The present invention belongs to the technical field of bioinformatics, and relates to a machine-learning-based method for screening cross-differentially expressed genes between lung cancer and COVID-19 infection and correspondingly screening prognostic genes of lung cancer. The method comprises: acquiring cross-differentially expressed genes between lung cancer and COVID-19; screening the cross-differentially expressed genes between lung cancer and COVID-19 infection; using Cox regression and LASSO regression to correspondingly screen prognostic genes of lung cancer; and using a K-M survival analysis method, GO and KEGG enrichment analysis methods and a protein-protein interaction analysis method to analyze screened-out prognostic genes of lung cancer. The method provided herein can process data, and can also identify intricate patterns in the data, and has relatively high sensitivity and specificity, thereby improving the efficiency and accuracy of screening. The technique can be extended to the research of other diseases, and features universality.
Resumen de: US20260053779A1
Disclosed are pharmaceutical formulations and methods using Verteporfin, Ribavirin, and/or Gemcitabine for use in the treatment of diseases by various routes of administration including inhalation, intratumoral, topical and/or systemic injection administration. This invention relates more specifically to the use of Verteporfin, Ribavirin, Gemcitabine, and/or combinations thereof as an inhaled dry powder treatment for COVID-19 and/or other lung infections, cancer and other non-cancer applications, which may be followed by other treatment regimens including radiation therapy, photodynamic therapy, and/or sonodynamic therapy. These pharmaceutical compositions containing one or more of Verteporfin, Ribavirin, and Gemcitabine may be included in pharmaceutical kits containing the compositions, and to methods for the treatment of cancer and non-cancer diseases with the active agents of the pharmaceutical compositions. The administering of Verteporfin alone or in combination with Ribavirin and Gemcitabine may be followed or co-administered with photodynamic and/or sonodynamic therapy (PDT/SDT).
Resumen de: US20260053745A1
Methods for prophylaxis, treatment, and reduction of infection, re-infection, and transmission rates of Coronaviruses and more particularly Coronavirus Disease 2019 (COVID-19) resulting from a SARS-CoV-2 viral infection with the use of a pharmaceutical preparation comprising one or more coated or uncoated digestive enzymes, such as pancreatic enzymes and porcine pancreatic enzymes are described herein.
Resumen de: US20260055061A1
Halophthalimides are disclosed. The halophthalimides may inhibit TNF-α activity, TNF-α synthesis, inflammation, inducible nitric oxide synthase, SARS-CoV-2 virus, or any combination thereof. The halophthalimides may be administered to a subject with a traumatic brain injury, an inflammatory disorder, an autoimmune disorder, a neurodegenerative disease, a viral infection, or any combination thereof. The disclosed halophthalimides have a structure according to Formula I, or a stereoisomer or pharmaceutically acceptable salt, solvate, or hydrate thereof,where R5 isAt least one of R2-R4 or Re is halo.
Resumen de: WO2024218171A1
Compounds of Formula (I), pharmaceutical compositions containing them and their use in the treatment of a SARS-CoV-2 infection.
Resumen de: AU2024298416A1
The present invention relates to monoclonal antibodies or antigen-binding portion thereof that have a potent neutralizing activity against Coronavirus, in particular against at least one virus selected from SARS-CoV-2, SARS-CoV-1 and variants thereof. The invention relates also to the use of such monoclonal antibodies or antigen-binding portion thereof in therapy, prophylaxis, and diagnosis of Coronavirus, in particular SARS-CoV-2 and/or SARS-CoV-1 dependent diseases.
Resumen de: US20260049994A1
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. Antibodies produced from an immune response against SARS-CoV-2 infection are used to analyze prior exposure to the virus. The present invention provides methods for detecting antibodies in response to SARS-CoV-2 infection in a single multiplex immunoassay.
Resumen de: US20260048058A1
The present disclosure relates to methods of treating Alzheimer's disease, diseases and/or conditions associated with Covid-19 infection, including long COVID, a post-acute infection syndrome, or symptoms of orthostatic intolerance comprising administration of a therapeutically-effective combination of a COX-2 inhibitor and an antiviral compound.
Resumen de: WO2026039749A1
Described herein are soluble HRC-based Hpopeptide inhibitors of coronaviruses identified using structure-guided design to incorporate charged or polar residues at specific sites in the peptide to enhance aqueous solubility. Also described are methods of treating a coronavirus infection using soluble HRC-based hpopeptide inhibitors.
Resumen de: US20260049062A1
Provided herein are compounds, pharmaceutical compositions, and methods for treating a SARS-CoV-2 infection.
Resumen de: US20260049367A1
The present invention relates to a reaction mixture suitable for use in the diagnosis of Covid-19 by isothermal amplification method.
Resumen de: US12551717B1
A therapy, treatment and process for inactivating and/or killing COVID-19 (Corona Virus Disease 2019) is provided, including a low-dose, full body, Ultraviolet A1 (UV-A1, 360-400 nm) photon therapy, wherein the UV-A1 photon therapy activates singlet oxygen (1O2), which inactivates and/or kills COVID-19. UV-A1 therapy of the present invention can also be used to help alleviate symptoms and secondary illnesses caused by COVID-19. UV-A1 therapy of the present invention can also be used to help alleviate and treat pre-existing conditions of people that are also suffering from COVID-19 and worsened by COVID-19.
Resumen de: US20260041660A1
Methods and compositions containing a phorbol ester or derivative of a phorbol ester are provided for prevention and treatment of sudden acute respiratory syndrome (SARS) coronavirus infection, including SARS-COV-2 infection and related COVID-19 disease. Also provided are methods and compositions for preventing and treating acute inflammatory conditions and related pathogenic injuries, including Acute Respiratory Distress Syndrome (ARDS) and cytokine storm syndrome (CSS) seen in severe SARS-COV-2/COVID-19 cases.
Resumen de: US20260041760A1
Prophylaxis, immune therapy and vaccine strategies for Covid-19 variants and comorbid conditions such as aging, diabetes, cancer, tuberculosis or HIV. In one mode of invention, the role of the C3 Amplification loop is defined and how it derails the SNS functions or immune function at fluid and tissue levels. The plasticity in subverting C3 amplification control mechanism contribute to survival strategies of SARS-CoV-2 that contributes to various variants that can be reactivated at any stage of life based on immune system of patient that may get compromised with comorbid diseases such as aging, diabetes, cancer and HIV. Therapeutic modulation takes into consideration plasticity of different patient needs and their comorbid conditions by developing varying formulation methods and its combination approaches.
Resumen de: US20260041761A1
Provided are a pharmaceutical composition for resisting infection with SARS-COV-2 or a mutant thereof, and a combined drug thereof. To solve the problem of the lack of effective prevention and treatment drugs for infection with SARS-COV-2 or a mutant virus thereof, provided are a recombinant protein vaccine and/or an adenovirus vaccine for preventing and/or treating an infection with SARS-COV-2 or a mutant thereof, and in particular, provided are a nasal spray administration compound formulation containing active ingredients of two vaccines, i.e., a recombinant protein vaccine and an adenovirus vaccine, and a combination of the two vaccines for nasal spray administration, which can induce generation of strong antibody and cellular immune responses in vivo and block the binding of a protein S of SARS-COV-2 to an ACE2 receptor of a host cell, thus enabling a host to resist coronavirus infection. Particularly, the present invention has good prevention and treatment effects on various mutant viruses.
Resumen de: US20260041762A1
The present invention relates to a production method of an inactivated SARS-CoV-2 vaccine, the method including: a step of bringing a SARS-CoV-2 containing solution or an inactivated SARS-CoV-2 containing solution into contact with a cellulose sulfate ester gel at a pH of 8 or more and 10 or less to adsorb the SARS-CoV-2 or the inactivated SARS-CoV-2 to the gel; then removing impurities; and then eluting and recovering the SARS-CoV-2 or the inactivated SARS-CoV-2.
Resumen de: WO2026031273A1
The present invention relates to the technical field of medicine and relates to a salt of a cyclic carbonate nucleoside compound and a crystal thereof, and a preparation method therefor and a use thereof. The salt of the cyclic carbonate nucleoside compound has a structure represented by formula I. When Y is hydrobromic acid and n=1, the salt of the nucleoside compound exists in crystal form A or crystal form B. Crystal form A has the advantages of good physical and chemical stability, good solid-state properties, good water solubility, low hygroscopicity, high oral bioavailability, etc., and can be used in the preparation of a drug for treating and/or alleviating related diseases caused by viruses (especially novel coronavirus, feline infectious peritonitis virus, respiratory syncytial virus, porcine epidemic diarrhea virus, feline calicivirus, etc.).
Resumen de: US20260041759A1
A solution has been discovered that provides a more effective Coronavirus vaccine. The solution is an mRNA vaccine encoding a SARS-CoV-2 nucleoprotein (N) (mRNA-N) in combination with an mRNA vaccine encoding SARS-CoV-2 spike protein(S) (mRNA-S). Chemically modified mRNA-N (pseudouridine) and/or chemically modified mRNA-S (pseudouridine) can be synthesized and packaged in lipid nanoparticles (LNP). In mouse and hamster models, it was shown that mRNA-N alone is immunogenic and can significantly diminish viral loads in the mouse lung after prime-boost intramuscular immunization. In addition, the combinatorial mRNA-N/mRNA-S vaccination induces substantially stronger protection against SARS-CoV-2 than vaccination with mRNA-S alone.
Resumen de: US20260042743A1
The invention relates to benzimidazole compounds, pharmaceutically acceptable salts thereof and its pharmaceutical compositions for reducing/treating viral infections. The present invention also relates to synthesis of such benzimidazole compounds. The present invention further relates to compositions which comprise such benzimidazole compounds or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination. The compounds of the invention are useful in reducing/treating viral infections particularly coronavirus infections caused by SARS-CoV, MERS-CoV and SARS-CoV-2.
Resumen de: US20260041751A1
The present invention provides a fusion protein which is useful as a vaccine antigen against infectious diseases. A fusion protein including (a) a combination of hemagglutinin and an N-terminal domain of SARS-COV-2, (b) a combination of PspA and a receptor binding domain of SARS-COV-2, (c) a combination of hemagglutinin and respiratory syncytial virus G protein, or (d) a combination of PspA and hemagglutinin, is useful as a vaccine antigen against infectious diseases.
Resumen de: EP4692109A1
It aims to provide a composition for inducing follicular helper T cell reactive to SARS-CoV-2. A partial peptide of the spike protein of SARS-CoV-2 is provided, which contains an amino acid sequence selected from the group consisting of the following (1) to (17) and has a full length of 15 or less amino acids:(1) FKIYSKHTPIN (SEQ ID NO: 1),(2) FQFCNDPFLGVYYHK (SEQ ID NO: 2),(3) KRFDNPVLPFN (SEQ ID NO: 3),(4) LLQYGSFCTQL (SEQ ID NO: 4),(5) PPAYTNSFTRGVYYP (SEQ ID NO: 5),(6) CSNLLLQYGSFCTQL (SEQ ID NO: 6),(7) SKRSFIEDLLFNKVT (SEQ ID NO: 7),(8) TGVLTESNKKFLPFQ (SEQ ID NO: 8),(9) TNGTKRFDNPVLPFN (SEQ ID NO: 9),(10) NQFNSAIGKIQ (SEQ ID NO: 10),(11) NFTISVTTEIL (SEQ ID NO: 11),(12) STEIYQAGSTPCNGV (SEQ ID NO: 12),(13) KVFRSSVLHST (SEQ ID NO: 13),(14) EIRASANLAAT (SEQ ID NO: 14),(15) NFTISVTTEILPVSM (SEQ ID NO: 15),(16) FIKQYGDCLGDIAAR (SEQ ID NO: 16), and(17) FIEDLLFNKVTLADA (SEQ ID NO: 17).
Resumen de: WO2026030724A1
Provided herein are recombinant SARS-CoV-2 Spike proteins and fragments thereof comprising the receptor binding domain (RBD), which have utility, for example, for elicitation of an immune response to SARS-CoV-2 in a subject. Also provided are nucleic acid molecules and vectors encoding these proteins, as well as methods of their use and production. In several implementations, the disclosed recombinant SARS-CoV-2 Spike proteins and fragments thereof comprising the RBD, can be used to generate an immune response to SARS-CoV-2 in a subject, for example to treat or prevent or reduce the severity of SARS-CoV-2 infection.
Nº publicación: US20260034097A1 05/02/2026
Solicitante:
MCLEAY MATTHEW T [US]
MCLEAY MATTHEW T
Resumen de: US20260034097A1
Disclosed are pharmaceutical formulations and methods using Verteporfin, Ribavirin, and/or Gemcitabine for use in the treatment of diseases by various routes of administration including inhalation, intratumoral, topical and/or systemic injection administration. This invention relates more specifically to the use of Verteporfin, Ribavirin, Gemcitabine, and/or combinations thereof as an inhaled dry powder treatment for COVID-19 and/or other lung infections, cancer and other non-cancer applications, which may be followed by other treatment regimens including radiation therapy, photodynamic therapy, and/or sonodynamic therapy. These pharmaceutical compositions containing one or more of Verteporfin, Ribavirin, and Gemcitabine may be included in pharmaceutical kits containing the compositions, and to methods for the treatment of cancer and non-cancer diseases with the active agents of the pharmaceutical compositions. The administering of Verteporfin alone or in combination with Ribavirin and Gemcitabine may be followed or co-administered with photodynamic and/or sonodynamic therapy (PDT/SDT).
BOPI
Sede Electrónica
